Benefits of enhanced infection prophylaxis at antiretroviral therapy initiation by cryptococcal antigen status
<p><strong>Objectives:</strong> To assess baseline prevalence of cryptococcal antigen (CrAg) positivity; and its contribution to reductions in all-cause mortality, deaths from cryptococcus and unknown causes, and new cryptococcal disease in the REALITY trial.</p> <p>&l...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Wolters Kluwer Health
2020
|